Q2/10 Results, Athersys (ATHX)
August 9th, 2010
No comments
Net loss for Q/2/10 was $3.1M or $0.16 per share. Read more…
Categories: Independent Equity Research, Q2 Earnings
Archive
Archive for the ‘Independent Equity Research’ Category
Q2/10 Results, Opexa Therapeutics (OPXA)
August 9th, 2010
No comments
OPXA’s Q2/10 net loss was $1.82 M or ($0.12) per share. Read more…
Categories: Independent Equity Research, Stem Cell Technology
Is It Safe, Yet for Stem Cell Equities
August 4th, 2010
No comments
The financial markets have thoroughly depreciated the stem cell universe but, many struggling stem cell companies are getting second, third and fourth chances Read more…
Categories: Independent Equity Research, Stem Cell Technology
Starting the Week, a Possible Earnings Hangover, 8/2-6/10
August 1st, 2010
No comments
After a big rally in July, investors could be in for another bout of economic jitters this week as the focus shifts from earnings to the weak job market. Read more…
Categories: Independent Equity Research, The Week: August 2-6/10
Tarix Pharmaceuticals’ TXA127 Receives Orphan Drug Designation for Stem Cell Engraftment
June 29th, 2010
No comments
Tarix Pharmaceuticals today announced that its drug, TXA127, has been granted Orphan Drug designation from the FDA as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS). Read more…
Categories: Independent Equity Research, Stem Cell Technology
INSERM, the EU Project REBORNE for Bone Defects Regeneration using Stem Cells and Biomaterials
June 9th, 2010
No comments
The objectives of REBORNE is to perform multi-centre clinical trials using advanced biomaterials and cells from autologous or allogeneic sources. 5 clinical trials in orthopedic and maxillofacial surgery will take place in 12 clinical centers spread over 8 European countries. Read more…
Categories: Independent Equity Research, Stem Cell Technology
IDE Clinical Trial for Critical Limb Ischemia Utilizing Autologous Concentrated Bone Marrow Aspirate, Biomet
June 7th, 2010
No comments
Biomet’s subsidiary, Biomet Biologics, has enrolled the 1st subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI). Read more…
Categories: Independent Equity Research, Regenerative Medicine
The Only Metric I Need, CEO’S Open Market Purchases, Aastrom Biosciences (ASTM)
May 26th, 2010
No comments
We are all looking for any signal that will propel a stock and one major indicator is the CEO investing his own money. Timothy Mayleben, CEO of ASTM filed another Form 4, this week with the SEC wiich is his 2nd open market purchase since becoming CEO in 12/09. Read more…
Categories: Independent Equity Research
Vatican Calls Synthetic Cell Creation – “Interesting”
May 24th, 2010
No comments
The Vatican praised scientists, who had created the world’s first synthetic cell, calling it an “interesting result” that could help cure disease. Read more…
Categories: Independent Equity Research
First Synthetic Life Form, Medical Science Might Be Changed Forever
May 23rd, 2010
No comments
A team of scientists at the J. Craig Venter Institute announced that they have successfully created a living organism with a completely synthetic genome. Read more…
Categories: Independent Equity Research
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.